Any permitted disclosures will be made only on a confidential "need to know" basis within your organization or to your independent ethics committee(s). Any other use, copying, disclosure or dissemination of this information is strictly prohibited unless expressly authorized in writing by BMS. Any supplemental information (eg, amendments) that may be added to this document is also confidential and proprietary to BMS and must be kept in confidence in the same manner as the conten ts of this document. Any person who receives this document without due authorization fr om BMS is requested to return it to BMS or Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 2promptly destroy it. All other rights reserved. References to BMS in this protocol may apply to partners to which BMS has transferred obligations, eg, a Contract Research Organization (CRO). Replace all previous version(s) of the protocol with this revised protocol and please provide a copy of this revised protocol to all study pers onnel under your supervision, and archive the previous versions. Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 3DOCUMENT HISTORY Document Date of Issue Summary of Change Revised Protocol 0431-May-2019•Fasting glucose testing was limited to the Screening Period; on- treatment glucose testing can be non-fasting. •Guidance for premedication was added.